Until more evidence is available, in this individualized risk and benefit decision-making, one should not assume that this risk is specific to semaglutide. Taken in total, the summary noted that currently available evidence suggests a possible association between semaglutide and NAION
These considerations highlight the need for future studies specifically designed to evaluate GLP-1RAs in patients at high risk of PsA, particularly those with subclinical inflammation or early musculoskeletal symptoms
Our team will guide you in choosing the right option for your needs, considering factors like efficacy, lifestyle, and medical history to create a personalized weight management plan
Fiber combats side effects : Leafy greens, broccoli, oats, quinoa, and berries help with digestion and reduce constipation
We compared a 6 and 12-month change in total body weight loss (TBWL) for those receiving monotherapy from the initiation of GLP-1 analogue therapy with those receiving combination therapy from the initiation of bupropion/naltrexone added-on therapy
